Healthcare organizations are accumulating more evidence about AI than ever before. Models are being validated, workflows piloted, users surveyed, and time savings quantified. Yet organizations routinely reach the end of a promising pilot without a clear case for broader adoption.
That does not necessarily mean the pilot failed. In many cases, it means the pilot answered a different question from the one the organization ultimately needs to decide.
Evidence is always evidence of something specific. A strong technical result can establish that a model performs well. Positive clinician feedback can establish that users find a tool useful. A reduction in documentation time can establish that one part of a workflow became more efficient.
What those results do not automatically establish is whether the product should be deployed at scale.
The Gap Between the Result and the Decision
Consider an AI tool designed to identify patients who may need additional clinical intervention. A pilot demonstrates strong performance, and clinicians report that the additional information is valuable.
But a health system considering enterprise adoption has to answer additional questions. Will clinicians consistently act on the cases the tool identifies? Does the organization have capacity to deliver the intervention? Does acting on the information improve outcomes? If it does, does that improvement create enough clinical, operational, or economic value to justify deployment?
The original evidence can be completely valid while leaving those questions unresolved.
This is where organizations can move too easily from evidence into inference. Technical performance is treated as evidence of clinical usefulness. Clinical usefulness becomes evidence of workflow impact. Workflow impact becomes an economic case, which then becomes justification for a purchasing decision.
Each step may ultimately prove correct. But each step is a separate proposition. Evidence does not automatically travel from one to the next.
Why Time Savings are a Good Example
AI pilots frequently demonstrate value through time savings, particularly in documentation and administrative workflows. If a tool reduces the time required to complete a task by several minutes, that is useful evidence.
The harder question is what those minutes mean to the organization.
They may allow clinicians to see more patients, finish documentation earlier, spend more time on care, or reduce work performed after hours. They may improve employee experience without changing direct labor expenses. In another workflow, the time saved at one step may simply expose a bottleneck further downstream.
All of those outcomes can matter. But they support different business cases.
The mistake is not measuring the time saved. It is converting “this task takes less time” into “this product produces enterprise ROI” without establishing the link between the two.
The same problem appears with other pilot metrics. Higher utilization does not necessarily demonstrate better outcomes. Strong satisfaction does not prove sustained adoption. More patients identified do not create value unless the organization can act on those findings effectively.
Successful Pilots Can Still Leave the Buying Question Unanswered
This helps explain a familiar pattern in healthcare technology: a pilot is declared successful, but the product does not move into enterprise deployment.
Sometimes the obstacle is procurement, security, integration, or organizational resistance. But sometimes the more fundamental problem is that the pilot never generated evidence relevant to the next decision.
A health system may know that the technology works without knowing whether the workflow changes enough to justify implementation. It may know that users like the product without knowing whether the economics work. It may even have evidence of clinical benefit without knowing whether that benefit accrues to the organization expected to pay.
In that situation, more enthusiasm does not close the gap.
Start With the Decision
Healthcare organizations do not need to turn every AI pilot into an exhaustive evidence program. But before choosing the easiest metric to collect, it is worth asking a more basic question:
What decision is this pilot supposed to make possible?
If the answer is whether the model performs adequately, technical validation may be sufficient. If the decision is whether to change a workflow, the evidence needs to address how work actually changes. If the decision is whether to fund enterprise deployment, the organization needs to understand where value is created, who captures it, and whether it is material enough to justify the investment.
For AI companies, this means judging evidence partly by the decision it enables a customer to make. For health systems, it means being more precise about what a positive pilot result actually establishes.
The important question is no longer simply whether there is evidence. It is whether the evidence answers the question the decisionmaker actually has.
The author, Arvita Tripati, is Founder & Principal at Vahana Labs.